Octreotide implant: Development discontinued

Endo said it will discontinue development of its octreotide implant to treat carcinoid syndrome following an annual review of its R&D assets. The company said the review identified certain commercial challenges for the indication, including the expected rate of physician acceptance and the expected rate of existing patients willing to switch therapies. Octreotide implant was in Phase II testing to treat carcinoid syndrome. ...